Suppr超能文献

肝细胞癌的免疫微环境特征。

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

机构信息

The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland.

Department of Pathology, Central Hospital affiliated with Shenyang Medical College, Shenyang, Liaoning Province, China.

出版信息

Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.

Abstract

Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies. To characterize the immune microenvironment in HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1-positive, and LAG-3-positive lymphocytes, CD163-positive macrophages, and PD-L1 expression in tumor and liver background from 29 cases of resected HCC. Expression of CD8 was reduced in tumor, and expression of CD163 was reduced at the tumor interface. Positive clusters of PD-L1 expression were identified in 24 of 29 cases (83%), and positive expression of LAG-3 on tumor-infiltrating lymphocytes was identified in 19 of 29 cases (65%). The expression of both PD-L1 and LAG-3 was increased in tumor relative to liver background. No association between viral status or other clinicopathologic features and expression of any of the IHC markers investigated was noted. LAG-3 and PD-L1, two inhibitory molecules implicated in CD8 T-cell tolerance, are increased in most HCC tumors, providing a basis for investigating combinatorial checkpoint blockade with a LAG-3 and PD-L1 inhibitor in HCC. .

摘要

肝细胞癌 (HCC) 常发生于慢性肝脏炎症的背景下,可能对新型免疫疗法有反应。为了描述 HCC 的免疫微环境,对 29 例切除的 HCC 肿瘤和肝背景中的 CD8 阳性 T 淋巴细胞、PD-1 阳性和 LAG-3 阳性淋巴细胞、CD163 阳性巨噬细胞和 PD-L1 表达进行了免疫组化染色。肿瘤中 CD8 的表达减少,肿瘤界面处 CD163 的表达减少。在 29 例中有 24 例(83%)鉴定出 PD-L1 表达阳性簇,在 29 例中有 19 例(65%)鉴定出肿瘤浸润淋巴细胞上 LAG-3 的阳性表达。与肝背景相比,肿瘤中 PD-L1 和 LAG-3 的表达均增加。未观察到病毒状态或其他临床病理特征与任何研究的免疫组化标志物的表达之间存在关联。LAG-3 和 PD-L1 是两种与 CD8 T 细胞耐受相关的抑制性分子,在大多数 HCC 肿瘤中增加,为在 HCC 中联合检查点阻断 LAG-3 和 PD-L1 抑制剂提供了基础。

相似文献

1
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.
3
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
5
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Hepatology. 2020 Dec;72(6):1987-1999. doi: 10.1002/hep.31206. Epub 2020 Oct 20.
6
Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
Cancer Immunol Res. 2019 May;7(5):805-812. doi: 10.1158/2326-6066.CIR-18-0499. Epub 2019 Mar 22.

引用本文的文献

1
Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.
Oncol Res. 2025 Aug 28;33(9):2353-2377. doi: 10.32604/or.2025.061422. eCollection 2025.
3
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma.
ILIVER. 2024 Feb 9;3(1):100083. doi: 10.1016/j.iliver.2024.100083. eCollection 2024 Mar.
5
Lactylation-Driven NUPR1 Promotes Immunosuppression of Tumor-Infiltrating Macrophages in Hepatocellular Carcinoma.
Adv Sci (Weinh). 2025 May;12(20):e2413095. doi: 10.1002/advs.202413095. Epub 2025 Apr 30.
6
Advances in Immunotherapy in Hepatocellular Carcinoma.
Int J Mol Sci. 2025 Feb 24;26(5):1936. doi: 10.3390/ijms26051936.

本文引用的文献

1
Immune oncology in hepatocellular carcinoma-hype and hope.
Lancet. 2017 Jun 24;389(10088):2448-2449. doi: 10.1016/S0140-6736(17)31044-9. Epub 2017 Apr 20.
3
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
J Immunother Cancer. 2017 Mar 21;5:23. doi: 10.1186/s40425-017-0228-3. eCollection 2017.
6
Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
Scand J Clin Lab Invest. 2016;76(1):64-73. doi: 10.3109/00365513.2015.1099722. Epub 2015 Nov 7.
7
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
8
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.
Liver Int. 2015 Sep;35(9):2155-66. doi: 10.1111/liv.12818. Epub 2015 Mar 25.
10
The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma.
PLoS One. 2013;8(3):e59771. doi: 10.1371/journal.pone.0059771. Epub 2013 Mar 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验